Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noam Pondé

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
ESMO Open|August 30, 2017
Cancer drugs, survival and ethics: a critical look from the insideMartine Piccart, Noam Pondé
Nature Reviews. Clinical Oncology|July 26, 2019
PERSEPHONE - implications for clinical practice in 2019Noam Pondé, Evandro de Azambuja
Chinese Clinical Oncology|January 9, 2018
Choice of chemotherapy regimen for early HER2-positive breast cancer in elderly patientsNoam Pondé, Evandro de Azambuja
Expert Opinion on Investigational Drugs|October 14, 2017
CDK4/6 blockade in breast cancer: current experience and future perspectivesDimitrios Zardavas, Noam Pondé, Konstantinos Tryfonidis
Current Treatment Options in Oncology|April 2, 2019
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive ReviewNoam Pondé, Philippe Aftimos, Martine Piccart
Ecancermedicalscience|December 1, 2016
Phosphoethanolamine and the danger of unproven drugsNoam Pondé, Evandro de Azambuja, Felipe Ades
ESMO Open|November 16, 2016
Threat posed by unproven drugs in medical oncologyNoam Pondé, Felipe Ades, Evandro de Azambuja
Future Oncology (London, England)|August 30, 2018
Mammaprint™: a comprehensive reviewMariana Brandão, Noam Pondé, Martine Piccart-Gebhart
NPJ Breast Cancer|January 25, 2019
PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?Noam Pondé, Richard D Gelber, Martine Piccart
Expert Review of Anticancer Therapy|March 25, 2016
Adjuvant chemotherapy in elderly patients with breast cancer: key challengesNoam Pondé, Lissandra Dal Lago, Hatem A Azim
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
ESMO Open|August 30, 2017
Cancer drugs, survival and ethics: a critical look from the insideMartine Piccart, Noam Pondé
Nature Reviews. Clinical Oncology|July 26, 2019
PERSEPHONE - implications for clinical practice in 2019Noam Pondé, Evandro de Azambuja
Chinese Clinical Oncology|January 9, 2018
Choice of chemotherapy regimen for early HER2-positive breast cancer in elderly patientsNoam Pondé, Evandro de Azambuja
Expert Opinion on Investigational Drugs|October 14, 2017
CDK4/6 blockade in breast cancer: current experience and future perspectivesDimitrios Zardavas, Noam Pondé, Konstantinos Tryfonidis
Current Treatment Options in Oncology|April 2, 2019
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive ReviewNoam Pondé, Philippe Aftimos, Martine Piccart
Ecancermedicalscience|December 1, 2016
Phosphoethanolamine and the danger of unproven drugsNoam Pondé, Evandro de Azambuja, Felipe Ades
ESMO Open|November 16, 2016
Threat posed by unproven drugs in medical oncologyNoam Pondé, Felipe Ades, Evandro de Azambuja
Future Oncology (London, England)|August 30, 2018
Mammaprint™: a comprehensive reviewMariana Brandão, Noam Pondé, Martine Piccart-Gebhart
NPJ Breast Cancer|January 25, 2019
PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?Noam Pondé, Richard D Gelber, Martine Piccart
Expert Review of Anticancer Therapy|March 25, 2016
Adjuvant chemotherapy in elderly patients with breast cancer: key challengesNoam Pondé, Lissandra Dal Lago, Hatem A Azim
Pageof 3